



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: SCHENK, Dale B.

Docket No: 15270J-004740US

Appln. No.: 09/322,289

Group Art Unit: 1649

Confirmation No.: 7773

Examiner: Kolker, Daniel E.

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.97 and §1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on April 16, 2007 with the United States Postal Service in an envelope as "Express Mail Post Office To Addressee," mailing label No. EV 843 555 401 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

4/16/07

Date

Erika Chiba

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of references 648-655, 662-666, 676-678, 681-682, 687-690, 694-701, 727-729, 731-739, 741-746, 749-757, 759, 765-769, 772-775, 786-794, 796-803, 806-818, 824, 826-848, 850-854, 856-859, and 861-865 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

04/19/2007 MBLAHCO 00000001 194880 09322289  
02 FC:1806 180.00 DR

Please note that references 643-675 were cited by the PTO/SB/08A and PTO/SB/08B forms submitted with the IDS filed December 7, 2005. It appears that this IDS was

not considered due to mailing of a Final Office Action on November 29, 2005. References 643-675 are cited by the PTO/SB/08A and PTO/SB/08B forms submitted herewith.

Applicant also cites the following copending applications which are directed to related subject matter and are commonly owned or under an assignment obligation to be commonly owned:

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;  
09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;  
09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;  
09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04 ;  
09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;  
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;  
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;  
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;  
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;  
10/934,818 filed 09/02/04;  
11/108,102 filed 04/15/05;  
11/245,524 filed 10/07/05;  
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;  
11/245,916 filed 10/7/05;  
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;  
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;  
10/816,380 filed 03/31/04; issued as US 7,014,855 on 03/21/06;  
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;  
10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;  
09/322,289 filed 05/28/99;

09/724,319 filed 11/27/00; Appeal Brief filed 10/10/06;  
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;  
10/429,216 filed 05/30/03;  
10/828,548 filed 04/19/04;  
10/923,471 filed 08/20/04;  
10/923,474 filed 08/20/04; Notice of Appeal filed 02/05/07;  
10/923,605 filed 08/20/04;  
10/923,469 filed 08/20/04;  
09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;  
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;  
11/058,757 filed 02/14/05;  
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;  
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;  
09/724,273 filed 11/28/00;  
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;  
09/724,288 filed 11/28/00;  
10/777,792 filed 02/11/04;  
10/890,000 filed 07/12/04;  
10/890,071 filed 07/12/04;  
09/723,765 filed 11/28/00;  
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;  
09/724,575 filed 11/28/00;  
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;  
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05; and  
09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239  
filed 06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01; Issued as US 7,189,819 on 03/13/07;

10/789,273 filed 2/27/04;

10/232,030 filed 08/30/02; Notice of Appeal filed 12/21/06;

10/388,389 filed 03/12/03; issued as US 7,179,892 on 02/20/07;

10/388,214 filed 03/12/03;

10/858,855 filed 06/01/04;

10/771,174 filed 02/04/04;

11/260,047 filed 10/26/05;

11/304,986 filed 12/15/05;

11/305,889 filed 12/15/05;

11/305,899 filed 12/15/05;

11/303,478 filed 12/15/05;

11/304,072 filed 12/15/05;

60/736,119 filed 11/10/05;

60/735,687 filed 11/10/05;

10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856 filed 01/31/04);

11/342,353 filed 01/27/06;

10/583,503 filed 06/16/06

11/454,772 filed 06/16/06.

11/516,724 filed 09/05/06;

11/520,438 filed 09/12/06; and

60/793,014 filed 04/18/06.

Applicant further cites the following commonly owned abandoned applications or abandoned applications under an assignment obligation to be commonly owned which are directed to related subject matter:

60/067,740 filed 12/02/97;

60/080,970 filed 04/07/98;

10/928,926 filed 08/27/04;

09/580,015 filed 05/26/00;

10/889,999 filed 04/12/04;

09/580,019 filed 05/26/00;

09/724,291 filed 11/28/00;

09/585,656 filed 06/01/00;

09/723,766 filed 11/27/00;

09/723,725 filed 11/27/00;

09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00);

09/579,690 filed 05/26/00;

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00;

09/724,929 filed 11/28/00;

60/137,010 filed 06/01/99;

60/137,047 filed 06/01/99;

60/136,655 filed 05/28/99,

09/723,544 filed 11/28/00.

09/497,553 filed 02/03/00;

09/723,713 filed 11/27/00;  
09/723,760 filed 11/27/00;  
09/724,495 filed 11/27/00;  
10/788,666 filed 02/27/04;  
09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed 05/26/00);  
10/822,968 filed 04/12/04;  
10/823,463 filed 04/12/04;  
10/890,024 filed 04/12/04;  
10/890,070 filed 07/12/04;  
10/923,267 filed 08/20/04;  
10/934,819 filed 09/02/04; and  
11/396,391 filed 03/30/2006.

Applicant also cites the following abandoned applications directed to related subject matter but subject to different assignment:

10/703,713 filed 11/07/03;  
10/704,070 filed 11/07/03;  
11/396,417 filed 03/30/06;  
11/413,638 filed 04/28/06;  
60/251,892 filed 12/06/00;  
60/444,150 filed 02/01/03;  
60/616,474 filed 10/05/04;  
60/530,481 filed 12/17/03;  
60/474,654 filed 05/30/03;

60/363,751 filed 03/12/02.  
60/622,525 filed 10/26/04;  
60/636,684 filed 12/15/04;  
60/636,842 filed 12/15/04;  
60/637,253 filed 12/16/04;  
60/636,810 filed 12/15/04;  
60/637,138 filed 12/16/04;  
60/636,776 filed 12/15/04;  
60/636,687 filed 12/15/04;  
60/736,045 filed 11/10/05;  
60/691,821 filed 06/17/05; and  
60/648,631 filed 01/28/05.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:


60/067,219 filed 12/03/97;  
60/079,697 filed 03/27/98;  
09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00; and,  
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 19-4880. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli  
Registration No. 42,397

SUGHRUE MION, PLLC  
Telephone: (650) 625-8100  
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE

**23493**

CUSTOMER NUMBER

Date: April 16, 2007  
RLC/JEO/CRF  
56890-1  
60652301 v1





Substitute for form 1449A/PTO			<b>Complete if Known</b>		
			Application Number	09/322,289	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
			Examiner Name	Kolker, D. E.	
Sheet	1	of	13	Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	855	7,195,761	03-27-2007	Holtzman et al.	
	686	6,972,127	12-06-2005	Schenk	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	658	6,905,686	06-14-2005	Schenk	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	673	6,808,712	10-26-2004	Schenk	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	849	6,727,349	04-27-2004	LaRosa et al.	
	675	6,710,226	02-23-2004	Schenk	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60652301

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
Examiner Name	Kolker, D. E.				
Sheet	2	of	13	Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	748	6,610,493	08-26-2003	Citron et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	702	6,548,640	04-15-2003	Winter	
	725	6,538,124	03-25-2003	Idusogie et al.	
	726	6,528,624	03-04-2003	Idusogie et al.	
	710	6,407,213	06-18-2002	Carter et al.	
	776	6,372,716	04-16-2002	Bush et al.	
	720	6,277,375	08-21-2001	Ward	
	777	6,270,757	08-07-2001	Warne	
	778	6,267,958	07-31-2001	Andya et al.	
	795	6,210,671	04-03-2001	Co	
	724	6,194,551	02-27-2001	Idusogie et al.	
	704	6,180,370	01-30-2001	Queen et al.	
	747	6,175,057	01-16-2001	Mucke et al.	
	719	6,165,745	12-26-2000	Ward et al.	
	723	6,121,022	09-19-2000	Presta et al.	
	711	6,054,297	04-25-2000	Carter et al.	
	722	5,869,046	02-09-1999	Presta et al.	
	707	5,859,205	01-12-1999	Adair et al.	
	860	5,858,981	01-12-1999	Schreiber et al.	
	771	5,837,268	11-17-1998	Potter et al.	
	779	5,770,700	06-23-1998	Webb et al.	
	780	5,744,132	04-28-1998	Warne et al.	
	770	5,733,548	03-31-1998	Restifo et al.	
	705	5,693,761	12-02-1997	Queen et al.	
	643	5,693,762	12-02-1997	Queen et al.	
	721	5,677,425	10-14-1997	Bodmer et al.	
	717	5,648,260	07-15-1997	Winter et al.	
	718	5,624,821	04-29-1997	Winter et al.	
	644	5,618,920	04-08-1997	Robinson et al.	
	764	5,601,827	02-11-1997	Collier et al.	
	706	5,585,089	12-17-1996	Queen et al.	
	781	5,385,887	01-31-1995	Yim et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60652301

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
Examiner Name	Kolker, D. E.				
Sheet	3	of	13	Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	645	5,258,498	11-02-1993	Huston et al.	
	703	5,225,539	07-06-1993	Winter	
	646	4,816,567	03-28-2989	Cabilly et al.	
	647	4,816,397	03-28-1989	Boss et al.	
	691	11/245,524	filed 10-07-2005	Schenk	
	692	11/245,916	filed 10-07-2005	Schenk	
	763	60/067,740	filed 12-02-1997	Schenk	
	760	60/067,219	filed 12-03-1997	Weiner et al.	
	761	60/079,697	filed 03-27-1998	Weiner et al.	
	762	60/080,970	filed 01-11-1999	Schenk	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	853	EP	921 189	B1	01-12-2005			
	842	EP	1 481 992	A2, A3	12-01-2004			
	786	EP	758 901	B1	02-26-1997			
	787	EP	758 248	B1	02-19-1997			
	738	EP	626 390	A1	11-30-1994			
	737	EP	620 276	A1	10-19-1994			
	802	EP	597 101	A1	05-18-1994			
	820	EP	285 159	A1	10-05-1988			
	848	WO	05/026211	A2, A3	03-24-2005			
	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	847	WO	04/071408	A2	08-26-2004			
	797	WO	04/055164	A2	07-01-2004			
	846	WO	04/044204	A2, A3	05-27-2004			
	796	WO	03/105894	A1	12-24-2003			
	845	WO	03/072036	A2, A3	09-04-2003			
	799	WO	03/39485	A2	05-15-2003			
	756	WO	03/16467	A2, A3	02-27-2003			
	803	WO	03/16466	A2	02-27-2003			
	788	WO	03/15691	A2	02-27-2003			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60652301

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1647
				Examiner Name	Kolker, D. E.
Sheet	4	of	13	Attorney Docket Number	15270J-004740US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	798	WO	03/09817	A2	02-06-2003			
	827	WO	02/96937	A2	12-05-2002			
	789	WO	01/05355	A2	01-25-2001			
	772	WO	99/10008	A1	03-04-1999			
	813	WO	97/03192	A3	01-30-1997			
	854	WO	95/07301	A1	03-16-1995			
	696	WO	95/06407	A1	03-09-1995			
	736	WO	94/10569	A1	05-11-1994			
	814	WO	94/00153	A1	01-06-1994			
	648	WO	91/09967	A1	07-11-1991			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60652301

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, D. E.	
Sheet	5	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell, 2nd Edition</i> , pages 266-267, Garland Publishing Inc., New York (1989).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	790	BALES et al., "Administration of an Anti-Aβ Fab Fragment to APP <sup>V717F</sup> Transgenic Mice Reduces Neuritic Plaque," Abstract P\$-396, Page S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based	
	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody," <i>J. Clin. Invest.</i> , 116(3):825-832 (2006).	
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against βA4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 in Vivo: Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).	
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <i>Free Press</i> , 7/23/01.	
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <i>J. Biol. Chem.</i> , 275(22):16941-16947 (2000).	
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <i>Exp. Neurol.</i> , 120(2):245-263 (1993).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, D. E.	
Sheet	6	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <u>Am. J. Public Health</u> , 88:1337-1342 (1998).	
	791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A $\beta$ Immunotherapy on Their Clearance," <u>Am. J. Pathology</u> , 165(3):987-995 (2004).	
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).	
	766	COICO et al., <u>Immunology A Short Course, Fifth Edition</u> , pages 18-24 (2003).	
	859	COMERY et al., "Passive Immunization Against $\beta$ -Amyloid Leads to Acute Cognition Improvement," <u>Society for Neuroscience</u> , abstract, Washington DC, 11/12-16/05.	
	687	COX et al., "Adjuvants---a classification and review of their modes of action," <u>Vaccine</u> , 15(3):248-256 (1997).	
	836	DAS et al., "Reduced effectiveness of A $\beta$ -42 immunization in APP transgenic mice with significant amyloid deposition," <u>Neurobiology of Aging</u> , 22:721-727 (2001).	
	769	DAVIS, S. S., "Nasal Vaccines," <u>Advanced Drug Delivery Reviews</u> , 51:21-42 (2001).	
	861	DE FELICE et al., " $\beta$ -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <u>Cell Mol. Neurobiol.</u> , 22(5/6):545-563 (2002).	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Rev. In Neurosciences</u> , 5:213-225 (1994).	
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998).	
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).	
	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <u>Blood</u> , 88(1):202-210 (1996).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, D. E.	
Sheet	7	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	817	DU et al., "α <sub>2</sub> -Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein," <u>J. Neurochemistry</u> , 69(1):299-305 (1997).	
	811	European Search Report of 5/22/06 for European Application 06075704.4-2107.	
	812	European Search REport of 5/22/06 for European Application 06075479.3-2107.	
	852	European Search Report of 1/16/07 for European Application 04776252.1-2405.	
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).	
	830	FOX et al., "Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease," <u>Brain</u> , 121:1631-1639 (1998).	
	831	FUKUTANI et al., "Cerebeller pathology in sporadic and familial Alzheimer's disease including APP 717 (Val->Ile) mutation cases: A morphometric investigation," <u>J. Neurologic Sci.</u> , 149:177-184 (1997).	
	807	HARA et al., "Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <u>J. Alzheimer's Disease</u> , 6:483-488 (2004).	
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).	
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <u>Int. J. Biochem. &amp; Cell Biol.</u> , 35:1608-1613 (2003).	
	662	IDA et al., "Analysis of Heterogeneous βA4 Peptides in Juman Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).	
	792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001).	
	834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <u>Biochemistry</u> , 41:922-928 (2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, D. E.	
Sheet	8	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).	
	863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(30):274-279 (2001).	
	843	KLYUBIN et al., "Anti-A $\beta$ Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus <i>In Vivo</i> by naturally Produced A $\beta$ Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).	
	794	KOFLER et al., "Immunoglobulin $\kappa$ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <u>J. Clin. Invest.</u> , 82:852-860 (1988).	
	826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	
	695	KUO et al., "Water-soluble A $\beta$ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <u>J. Biol. Chem.</u> , 271(8):4077-4081 (1996).	
	833	KUO et al., "Comparative Analysis of Amyloid- $\beta$ Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <u>J. Biol. Chem.</u> , 276(16):12991-12998 (2001).	
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).	
	816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to $\beta$ -Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994).	
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , 166(3):1748-1754 (2001).	
	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004).	
	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity &amp; Aging</u> , 1:1-2 (2004).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kolker, D. E.
Sheet	9	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).	
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).	
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).	
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).	
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).	
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 ( $\beta$ -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).	
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).	
	841	OKIE, S., "Promising Vaccine Targets Ravager of Minds," <u>Washington Post</u> , page A01, 5/8/01.	
	808	OKURA et al., "Nonviral A $\beta$ DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006).	
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
	829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <u>J. Am. Soc. Exp. Neurotherapeutics</u> , 2:3-14 (2005).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, D. E.	
Sheet	10	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).	
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	
	806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.	
	850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.	
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989).	
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).	
	864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993).	
	837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01.	
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor $\alpha$ ," <u>PNAS</u> , 92:11294-11298 (1995).	
	809	QU et al., "A $\beta_{42}$ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006).	
	838	ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5.	
	865	ROSES, A.D., "Apolipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996).	
	655	RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Application Number	09/322,289
			Filing Date	May 28, 1999
			First Named Inventor	Schenk, Dale B.
			Art Unit	1649
Examiner Name	Kolker, D. E.			
Attorney Docket Number	15270J-004740US			
Sheet	11	of	13	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	851	SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999).	
	759	SCHENK et al., "Current progress in beta-amyloid immunotherapy," <u>Curr. Opin. Immunology</u> , 16(5):599-606 (2004).	
	768	SCHMITT et al., "Interactions of the alzheimer $\beta$ amyloid fragment <sub>(25-35)</sub> with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).	
	856	SEUBERT et al., "Antibody Capture of Soluble A $\beta$ does not Reduce Cortical A $\beta$ Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , (2007).	
	818	SHINKAI et al., "Amyloid $\beta$ -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).	
	828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.	
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	
	678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	
	839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?@," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from internet (1999).	
	857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005).	
	767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).	
	844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from <a href="http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525">http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525</a> on 2/8/97, "HV54_Mouse" (11/1/90).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, D. E.	
Sheet	12	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	815	URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).	
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).	
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	
	835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <u>Progress in Neurobiology</u> , 61:305-312 (2000).	
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002).	
	800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).	
	801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).	
	676	<u>Webster's New World Dictionary</u> , page 1387, therapeutic (1988).	
	688	<u>Webster's New World Dictionary of American English</u> , Third College Edition, page 1078 (1988).	
	765	WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997).	
	739	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996).	
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.	
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kolker, D. E.
Sheet	13	of	13	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.	
	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <u>Scand. J. Immunol.</u> , 46(2):175-179 (1997).	
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- $\beta$ : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strateies, Amyloid-Based	
	810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and $\beta$ -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.